BioTuesdays

Category - News

KalVista Pharmaceuticals Logo
Markets

Stifel starts KalVista Pharma at buy; PT $33

Stifel initiated coverage of KalVista Pharmaceuticals (NASDAQ:KALV) with a “buy” rating and $33 price target. The stock closed at $18.76 on Oct. 12. “Our bullish thesis on the stock centers around lead asset, KVD900, an...

October 15, 2018
Vascular Biogenics
Markets

HCW ups Vascular Biogenics to buy; PT $3

H.C. Wainwright upgraded Vascular Biogenics (NASDAQ:VBLT) to “buy” from “neutral” but maintained its $3 price target, citing a 46% stock price decline since March, despite no negative news. The stock closed at $1.42 on...

October 15, 2018
Profound Medical Logo
Markets

Echelon names Profound Medical as Top Pick

Echelon Wealth Partners has named Profound Medical (TSX:PRN; OTCQX:PRFMF) as a Top Pick with a “buy” rating and $3 price target. The stock closed at 60 cents on Oct. 10. Commenting on Profound’s share price softness in...

October 12, 2018
Immune Design
Markets

Leerink cuts Immune Design to MP; PT to $3 from $7

Leerink downgraded Immune Design (NASDAQ:IMDZ) to “market perform” from “outperform” and cut its price target to $3 from $7 after the company deprioritizedlead program, CMB305, a therapeutic cancer vaccine targeting NY...

October 12, 2018
AcelRx Pharma Logo
Markets

Ladenburg ups AcelRx Pharma PT to $10 from $7

Ladenburg Thalmann raised its price target for AcelRx Pharmaceuticals (NASDAQ:ACRX) to $10 from $7 after the FDA released briefing documents ahead of Friday’s meeting to discuss the company’s drug candidate, Dsuvia. The...

October 11, 2018
Quanterix
Markets

Canaccord starts Quanterix at buy; PT $27

Canaccord Genuity initiated coverage of Quanterix (NASDAQ:QTRX) with a “buy” rating and $27 price target. The stock closed at $18.37 on Oct. 9. “We view Quanterix as a precision medicine pure-play well positioned to...

October 10, 2018
LeMaitre Vascular
Markets

Roth ups LeMaitre Vascular to buy; PT cut to $34

Roth Capital Partners upgraded LeMaitre Vascular (NASDAQ:LMAT) to “buy” from “neutral” but reduced its price target to $34 from $39 after the company reported in-line EPS for the third quarter of 2018, despite a $1.8...

October 8, 2018